Study Tests Elimination Of Chemotherapy And Expands Upon Previous Combination Study Of NK Cell Therapy With N-803 Showing Promising Clinically Meaningful Responses In Merkel Cell Carcinoma Patients CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 9, 2019-- NantKwest Inc .
CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 5, 2019-- NantKwest (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7th Second Round Crossover Funding Brings Celgene’s Investment to $105M in NantCell Valued at $4 Billion Currently Enrolling Patients in Advanced Stage Trials in 15 Indications for
Novel Trispecific CD19.t-haNK TM Natural Killer Cell Therapy Engineered for Enhanced Tumor Homing for B Cell Lymphoma CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 3, 2018-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the
NantKwest to Participate at Upcoming Investment Conferences CULVER CITY, CALIFORNIA-(BUSINESS WIRE), November 12, 2018 NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be participating at a number of investment
Combination in 30 Patients with Advanced Metastatic Cancer Refractory to Multiple Previous Therapies Zero Incidence of Cytokine Release Syndrome in Any of the 300 Doses in 30 Patients All Patients Received NK Cell Infusion and Novel Cancer Memory Vaccine Combination as Outpatients with No
Update on Off-The-Shelf CD16 Targeted NK Cell (haNK) and NANT Cancer Vaccine Program Including Interim Data Analysis for Pancreatic Cancer, Triple Negative Breast Cancer & Head and Neck Cancer Trials CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 5, 2018-- NantKwest (NASDAQ: NK), a leading,
CULVER CITY, Calif. --(BUSINESS WIRE)--Oct. 2, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at the upcoming Cantor Global Healthcare Conference on Tuesday, October 2 nd in New York City
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 19, 2018-- NantKwest, Inc. (Nasdaq: NK) today announced the elevation of Sonja Nelson , chief accounting officer for the company, to the role of Chief Financial Officer (CFO). This press release features multimedia.
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 5, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong , Chairman & CEO of NantKwest , will be presenting and conducting one-on-one meetings at the upcoming
